Researchers at the Medical University of South Carolina Hollings Cancer Center identified a resistance mechanism in triple-negative breast cancer involving lysyl oxidase (LOX) and reported a preclinical “one-two punch” strategy. The team, led by Ozgur Sahin, found that LOX inhibition disrupts processes TNBC depends on, creating a vulnerability that can be exploited by blocking a second survival pathway. In Cell Reports Medicine, the combination reduced tumor growth in multiple preclinical TNBC models without chemotherapy, aiming to avoid the toxicity profile associated with standard regimens. The paper describes the approach as first weakening cancer cells via LOX blockade, then delivering a second therapeutic hit after tumors adapt. For translational teams, the work provides a mechanistic route to potentially treat chemoresistant TNBC by converting resistance mechanisms into targetable dependencies, though the results remain preclinical.